Healthcare PharmaceuticalsRotaTeq
Owned by Merck & Co.
Merck's live oral pentavalent rotavirus vaccine (RV5), FDA approved February 3, 2006, developed by Paul Offit and colleagues at Children's Hospital of Philadelphia, containing five human-bovine reassortant rotavirus strains (G1, G2, G3, G4, and P1A) administered as a 3-dose oral series to infants, recommended by the CDC for routine infant immunization.
vaccinerotaviruspentavalent